PSC
CLVS

Piper Sandler & Co’s Clovis Oncology, Inc. CLVS Stock Holding History

Piper Sandler & Co’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,500
Closed -$308K – 136
2015
Q2 		$308K Sell
3,500
-500
-13% -$42.8K 0.18% 63
2015
Q1 		$297K Buy
+4,000
New +$282K 0.12% 80

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Piper Sandler & Co's CLVS Position: Q3 2015 in Review

Piper Sandler & Co sold out of Clovis Oncology, Inc. (CLVS) in Q3 2015, closing a stake of 3,500 shares — an estimated $308K sold.

Piper Sandler & Co first reported a position in CLVS in Q1 2015 and held it in 2 quarters. The position peaked at $308K in Q2 2015. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2015.

  • Piper Sandler & Co reported no remaining Clovis Oncology, Inc. position as of Q3 2015 after selling out during the quarter.
  • Piper Sandler & Co sold 3,500 Clovis Oncology, Inc. shares in Q3 2015, an estimated $308K.
  • Piper Sandler & Co first reported a position in Clovis Oncology, Inc. in Q1 2015 and held it in 2 quarters.
  • Piper Sandler & Co's Clovis Oncology, Inc. position peaked at $308K in Q2 2015.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2015.

Based on Piper Sandler & Co's 13F filing for Q3 2015, filed 16 Nov 2015.